Structure via PubChem · Public domain (PubChem)
prazepam
Sign in to saveAlso known as Centrax®, W-4020, Prazepamum
Prazepam is a benzodiazepine derivative drug developed by Warner-Lambert in the 1960s. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Prazepam, (Elimination half-life 29-224h), is a prodrug for desmethyldiazepam, (Elimination half-life 36-200h), which is responsible for the therapeutic effects of prazepam.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464213409
- Drug.IUPAC_name
- 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
- Drug.image
- Prazepam.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 180
- Drug.image2
- Prazepam3d.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 140
- Drug.MedlinePlus
- a601036
- Drug.legal_BR
- B1
- Drug.legal_CA
- Schedule IV
- Drug.legal_DE
- Rx-only/Anlage III
- Drug.legal_US
- Schedule IV
- Drug.routes_of_administration
- Oral
- Drug.metabolism
- Hepatic
- Drug.elimination_half life
- 36–200 hours
- Drug.excretion
- Renal
via Wikipedia infobox
Chemical data
- Formula
- C19H17ClN2O
- Molecular weight
- 324.8 g/mol
- IUPAC name
- 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
- SMILES
- C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4
- InChIKey
- MWQCHHACWWAQLJ-UHFFFAOYSA-N
- XLogP
- 3.6
- Polar surface area
- 32.7 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1982
- Admin. routes
- oral
- Indications
- anxiety
via ChEMBL · EBI
Research
232 papers- Prazepam.IARC monographs on the evaluation of carcinogenic risks to humans · 1996
- Prazepam and lorazepam, two new benzodiazepines.The New England journal of medicine · 1978
- [Managing benzodiazepine withdrawal using prazepam substitution: Retrospective study of 86 patients].Therapie · 2026
- Prazepam metabolism in female subjects.The Journal of pharmacy and pharmacology · 1980
- Comparative single-dose kinetics of oxazolam, prazepam, and clorazepate: three precursors of desmethyldiazepam.Journal of clinical pharmacology · 1984
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 324.102941
- Has use
- medication
Show 6 more facts
- defined daily dose
- 30
- chemical formula
- C₁₉H₁₇ClN₂O
- Commons category
- Prazepam
- medical condition treated
- focal epilepsy
- MCN code
- 2933.91.73
- canonical SMILES
- C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4
via Wikidata · CC0
~5 min read
Encyclopedic overview
14 sectionsContents
- Indications
- Side effects
- Tolerance, dependence and withdrawal
- Contraindications and special caution
- Mechanism of action
- Pharmacokinetics
- Interactions
- Overdose
- Abuse potential
- Toxicity
- Trade names
- See also
- References
- External links
Prazepam is a benzodiazepine derivative drug developed by Warner-Lambert in the 1960s. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Prazepam, (Elimination half-life 29-224h), is a prodrug for desmethyldiazepam, (Elimination half-life 36-200h), which is responsible for the therapeutic effects of prazepam.
== Indications == Prazepam is indicated for the short-term treatment of anxiety. After short-term therapy, the dose is usually gradually tapered-off to reduce or avoid any withdrawal or rebound effects. Desmethyldiazepam, an active metabolite, has a very long half-life of 36 to 200 hours, which contributes to the therapeutic effects of prazepam.
Excerpted from Wikipedia’s “prazepam” article, available under the CC BY-SA 4.0 licence.